Inhibitor Therapeutics INTI
OTC INTI
$0.11 +0.00 (+0.00%)
At close: Oct 20, 2026 · 4:00 PM EDT

Inhibitor Therapeutics (INTI) Other Non-Current Liabilities (2012)

Updated

Inhibitor Therapeutics (INTI) reported Other Non-Current Liabilities of $509,266 for Q4 2012.

Analysis

Inhibitor Therapeutics (INTI) Other Non-Current Liabilities (2012) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,165.22 Bn 1,133.81 Bn 19.71 Bn
2 Johnson & Johnson 646.28 Bn 566.14 Bn 17.30 Bn
3 AbbVie 503.17 Bn 476.28 Bn 12.70 Bn
4 Merck 365.23 Bn 319.60 Bn 12.21 Bn
5 Novartis Ag 302.66 Bn 266.65 Bn 11.24 Bn
6 Astrazeneca 267.39 Bn 241.08 Bn 12.86 Bn
7 Amgen 241.61 Bn 197.01 Bn 7.24 Bn
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn
9 Pfizer 172.91 Bn 119.55 Bn 10.94 Bn
10 Inhibitor Therapeutics 19.12 Mn 11.93 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2012 509,266.00
API Access

Inhibitor Therapeutics Other Non-Current Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=other-non-current-liabilities&ticker=INTI&period=max&api_key=YOUR_API_KEY